Author: Ravi Shankar

• New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)
• The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savings
• The breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how therapies perform in patients’ everyday lives to assist in improving routine care and reducing the burden of severe mental illness

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and healthcare costs compared with other treatment options. The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

“We cannot accept psychiatric emergencies and hospitalizations as an inevitable part of living with schizophrenia and bipolar I disorder,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “These findings show that when we provide a treatment option like UZEDY that helps patients stay on track, we can meaningfully cut emergency room visits and help people maintain stability in their everyday lives. Delivering measurable impact for patients and healthcare systems is what drives everything we do at Teva.”

Schizophrenia Data Highlights

The two schizophrenia abstracts featured at Psych Congress highlight significant clinical and economic advantages in real-world settings:

• Lower Emergency Care and Costs vs. Paliperidone Palmitate Once-Monthly (PP1m): In a matched cohort of 1,166 patients (583 per group), fewer patients receiving once-monthly UZEDY had an emergency department (ED) visit compared to PP1m (22.0% vs. 27.8%). Overall, UZEDY patients had a 40% lower all-cause ED visit rate and a numerically lower proportion of inpatient hospitalizations (11.1% vs. 14.8%). Estimated mean monthly direct healthcare costs were significantly lower for UZEDY ($4,688.10 vs. $5,724.80), delivering an adjusted mean monthly savings of $1,036.70 per patient.
• Superior Adherence and Persistence vs. Other Long-Acting Injectable Antipsychotics: Matched cohorts compared once-monthly UZEDY to risperidone microspheres every-2-weeks, aripiprazole once-monthly and haloperidol decanoate once-monthly. The greatest differences were observed against risperidone microspheres, where UZEDY patients achieved 3.6x higher odds of adherence (OR: 3.6), an 80% lower likelihood of discontinuation (OR: 0.2) and lower rates of ED visits and hospitalizations. UZEDY patients also had lower ED visit rates versus haloperidol decanoate once-monthly, while outcomes versus aripiprazole once-monthly were generally comparable.

“As clinicians, it is frustrating to watch patients with schizophrenia struggle through cycles of relapse and end up back in the emergency room,” said John M. Kane, MD, Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. “We need to think differently about how we use long-acting injectables. This observational data shows that patients receiving UZEDY had greater treatment continuity and fewer emergency department visits, reinforcing the potential of this approach to help patients stay stable while reducing pressure on an already strained healthcare system.”

BD-I Data Highlights

Teva also presented new study findings evaluating outcomes in patients living with BD-I who switched from oral antipsychotics to UZEDY:

• Real-World Effectiveness of Switching From Oral Antipsychotics to UZEDY in BD-I: A retrospective chart review of 358 matched patients (179 per group) evaluated patient outcomes after transitioning from oral antipsychotics to either UZEDY or another oral antipsychotic. Patients who switched to UZEDY experienced significantly less treatment failure (47% vs. 63%) compared to those switched to another oral antipsychotic. Patients receiving UZEDY were also more likely to stay on treatment longer without experiencing BD-I/mania-related hospitalizations, ED visits or discontinuation due to inadequate effectiveness.

As the treatment landscape for severe mental illness continues to evolve, real-world evidence remains essential in guiding clinical decisions that optimize patient outcomes and healthcare resources. These findings further validate UZEDY as an innovative, effective and economically beneficial treatment option for patients navigating the complex, daily challenges of schizophrenia and BD-I.

About UZEDY
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. In clinical trials, UZEDY significantly delayed time to relapse in adults with schizophrenia.^1,2 UZEDY administers risperidone through copolymer technology under license from Medincell that allows for rapid absorption and sustained release after subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.¹ For full prescribing information, visit https://www.uzedy.com/globalassets/uzedy/prescribing-information.pdf.

APPROVED USE

UZEDY (risperidone) extended-release injectable suspension is a prescription medicine used in adults

• for the treatment of schizophrenia
• for the maintenance treatment of bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about UZEDY?

UZEDY can cause serious side effects, including an increased risk of death in elderly people who are confused, have memory loss, and have lost touch with reality (dementia-related psychosis). UZEDY is not approved for use in patients with dementia-related psychosis.

Do not receive UZEDY if you are allergic to risperidone, paliperidone, or any of its components.

UZEDY may cause serious side effects, including:

• Stroke in elderly people (cerebrovascular problems) that can lead to death.
• Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can lead to death. Seek medical attention right away if you have any of these symptoms: high fever, severe muscle stiffness, confusion, sweating, irregular heartbeat, fast heart rate, or changes in your blood pressure.
• Uncontrolled facial or body movements (tardive dyskinesia) that may not go away, even if you stop receiving UZEDY. Tardive dyskinesia may also start after you stop receiving UZEDY.
• Problems with your metabolism that may include high blood sugar (hyperglycemia), diabetes mellitus, changes in the fat levels in your blood (dyslipidemia), and weight gain. Extremely high blood sugar can lead to coma or death. If you have diabetes or are at risk for diabetes (e.g., obesity, family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with UZEDY. Call your healthcare provider if you have symptoms of high blood sugar including: feeling very thirsty, hungry, sick to your stomach, weak or tired, or confused; needing to urinate more than usual; or your breath smells fruity.
• High levels of prolactin in your blood. UZEDY may cause a rise in the blood levels of a hormone called prolactin that may cause side effects including missed menstrual periods, decreased fertility in women, leakage of milk from the breasts, development of breasts in men, or problems with erection.
• Decreased blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
• Falls. Antipsychotic medicines like UZEDY may cause drowsiness or dizziness when you are standing, which could increase your risk for falls and related injuries.
• Low white blood cell count.
• Problems thinking clearly and moving your body. Do not drive, operate machinery, or do other dangerous activities until you know how UZEDY affects you.
• Seizures (convulsions).
• Difficulty swallowing that can cause food or liquid to get into your lungs.
• Prolonged or painful erection lasting more than 4 hours. Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
• Problems with control of your body temperature (too high or too low). Avoid getting overheated or dehydrated.

The most common side effects of risperidone in patients with

• Schizophrenia included slow movements, stiffness, shaking, restlessness, abnormal muscle contractions or movements, drowsiness, dizziness, anxiety, blurred vision, nausea, vomiting, indigestion, diarrhea, increased saliva, constipation, dry mouth, increased appetite, weight gain, tiredness, rash, and common cold symptoms
• Bipolar disorder were weight increased (5% in monotherapy trial) and slow movements, stiffness, shaking (≥10% in adjunctive therapy trial).
• Injection site reactions including a lump or itching were reported with UZEDY.

These are not all the possible side effects of UZEDY. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.

Do not drink alcohol during treatment with UZEDY.

Before receiving UZEDY, tell your healthcare provider about all your medical conditions, including if you:

• have had Neuroleptic Malignant Syndrome.
• have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia).
• have diabetes or have a family history of diabetes.
• have had dizziness or fainting or are being treated for high blood pressure.
• have had a low white blood cell count.
• have or have had seizures or epilepsy.
• are pregnant or plan to become pregnant during treatment with UZEDY. It is not known if UZEDY will harm your unborn baby. Use of UZEDY during the third trimester of pregnancy may cause side effects in the newborn infant, including agitation, abnormal muscle tone, tremor, drowsiness, difficulty feeding, and difficulty breathing. Seek medical attention if you notice these signs. If you become pregnant during treatment with UZEDY, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics, or call 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
• are breastfeeding or plan to breastfeed. If you are receiving UZEDY and are breastfeeding, monitor your infant for sleepiness, inadequate weight gain, jitteriness, tremors, and abnormal muscle movements. Seek medical care if you notice these signs.
• have or have had kidney or liver problems.

Tell your healthcare provider about all the medicines you take or plan to take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. UZEDY and other medicines may affect each other.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For more information about UZEDY, see the full Prescribing Information including Boxed WARNING, or talk to your healthcare provider.

About Schizophrenia
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.³ Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.^3,4,5 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 2.2 million people in the U.S. are currently diagnosed with the condition.^4,5,6 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.³ The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.⁵ Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.^7,8,9 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.^3,4,5,7,8,9 

About Bipolar I Disorder
Bipolar I Disorder (BD-I) is a serious mental health condition defined by episodes of mania—periods of abnormally elevated or irritable mood with increased energy and activity—and often episodes of depression. These episodes can cause significant disruptions in thinking, behavior, and daily functioning. It is challenging to diagnose and is often accompanied by other psychiatric comorbidities. BD-I is associated with poor long-term outcomes and a substantial increase in mortality compared to the general population from both suicide and cardiovascular disease. An estimated 1% or 3,400,000+ of U.S. adults will develop BD-I in their lifetime.¹⁰

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize UZEDY (risperidone) for the treatment of schizophrenia and bipolar I disorder; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors,” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

1. UZEDY^® (risperidone) extended-release injectable suspension, for subcutaneous injection Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc.
2. Data on file. [CSR/RISE]. West Chester, PA: Teva Neuroscience, Inc.
3. Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed March 2026.
4. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.
5. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.
6. DRG / Clarivate (Nov 2025 Market Forecast Assumptions-Schizophrenia)
7. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223. 
8. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. 
9. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615. 
10. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–552. doi:10.1001/archpsyc.64.5.543 

Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries: TevaIR@Tevapharm.com

• In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-‘749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-‘749 for ≥ 6 months met criteria for remission 
• Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-‘749 from existing regimens
• Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-‘749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-‘749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-‘749 as a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults. The findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.

“These findings further validate the long-term clinical profile of TEV-‘749 and its potential to be a once-monthly subcutaneous injectable olanzapine treatment that can help support stabilization for people living with schizophrenia,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “For those currently taking daily oral olanzapine and may be interested in switching to an LAI, these data suggest that TEV-‘749 can support long-term symptom control, helping to potentially fill an unmet need for this patient community.”

Olanzapine is the most widely prescribed atypical antipsychotic for schizophrenia as a daily oral treatment.¹ However, daily options may make it difficult to sustain long-term symptom improvement due to challenges with adherence, increasing the risk for instability and relapse.²

Long-Term Data Show High Stabilization and Low Rates of Relapse

In a post hoc analysis of the long-term treatment open-label period of the Phase 3 SOLARIS trial, more than half of all participants receiving TEV-‘749 achieved stabilization, more than one-fifth of long-term trial participants met criteria for remission (defined as maintaining a Positive and Negative Syndrome Scale [PANSS] item score of 3 or lower for at least six consecutive months across eight specific remission items), and few that had reached stabilization relapsed.

• Among 411 participants, 231 (56% [61%, 54%, and 54% with 318-, 425-, and 531-mg dose groups, respectively]) achieved stabilization
• Among 231 participants who achieved stabilization, only 10 (4% [6%, 1%, and 5%]) experienced relapse
• Among 183 participants who were treated with TEV-‘749 for six or more months, 39 (21% [26%, 13%, and 26%]) achieved remission

“These TEV-‘749 data are compelling because the vast majority of patients who start or respond well to olanzapine are treated with a daily oral pill of olanzapine,” said Christoph Correll, MD, Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY. “We know that long-acting injectable treatment options may support stability and reduce risk of relapse, and TEV-‘749 has the potential to offer many of these individuals the efficacy of olanzapine in a once-monthly formulation.”

Data Support Direct Switching from Daily Pills or Short-Acting Injections to Once-Monthly TEV-‘749

In separate analyses simulating potential switching scenarios in the inpatient, initiation of TEV-‘749 one day after the last dose of oral or short-acting intramuscular olanzapine resulted in predictable olanzapine exposures that remained within established oral therapeutic ranges. The findings offer clinical insights into how healthcare providers may switch patients to TEV-‘749 who are currently taking other olanzapine formulations.

Finally, an analysis of metabolic outcomes found that the metabolic profile of TEV-‘749 was consistent with daily oral olanzapine formulations, with no clear dose-dependent pattern observed. These data add to the broader safety and tolerability findings from the SOLARIS program.

Below is the full set of olanzapine LAI (TEV-‘749) posters being presented by Teva at Psych Congress 2026:

• (De novo) Durability of Response With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Schizophrenia: Post Hoc Analysis of the Phase 3 SOLARIS Trial
• (De novo) Population Pharmacokinetic Simulations of Inpatient Switching From Oral or Short-Acting Intramuscular Olanzapine to TV-44749
• (De novo) Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Efficacy Results From the Phase 3 SOLARIS Trial
• (De novo) Characterization of the Body Weight and Metabolic Profile of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749): Results From the Phase 3 SOLARIS Trial
• (Modified encore) Joint Population Pharmacokinetic Model of Oral, Intramuscular, and Subcutaneous (TV-44749) Olanzapine to Support TV-44749 Dosing and Switching Strategies

TEV-‘749 is an investigational once-monthly subcutaneous LAI of the second-generation antipsychotic olanzapine. It is not approved by any regulatory authority for any use at this time.

TEV-‘749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine.

A PDUFA decision from the FDA is expected for TEV-‘749 in Q4 2026. In the EU, the European Medicines Agency accepted the Marketing Authorization Application for TEV-‘749 in May 2026.

About Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS)
SOLARIS was a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-64 years) with schizophrenia.¹ For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (low, medium or high dose) or placebo in a 1:1:1:1 ratio.¹ For period two (next 48 weeks), patients who completed period one on placebo were re-randomized and equally allocated to one of the three olanzapine LAI treatment groups, while patients who completed period one on active olanzapine LAI remained on their established dose strength.¹ The end-of-treatment and follow-up visits were 4 and 8 weeks after administration of the last treatment dose, respectively.¹ The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of olanzapine LAI in adult patients with schizophrenia, as measured by PANSS.¹ A key secondary objective was to further evaluate the efficacy of olanzapine LAI based on additional parameters in adult patients with schizophrenia, as measured by CGI-S and PSP.¹ A secondary objective of period two of the study was to evaluate the safety and tolerability of olanzapine LAI in adult patients with schizophrenia.¹ 

About Schizophrenia
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.² Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.^2,3,4 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 2.2 million people in the U.S. are currently diagnosed with the condition.^3,4 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.⁴ The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.⁴ Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.^5,6,7 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.^2,3,4,5,6,7

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop olanzapine LAI (TEV-‘749) for the treatment of adult patients diagnosed with schizophrenia and to obtain regulatory FDA approval; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors,” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1. Data on file. [CSR/SOLARIS]. West Chester, PA: Teva Neuroscience, Inc.
2. Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed February 2026.
3. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.
4. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.
5. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223.
6. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50.
7. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615.

Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries
TevaIR@Tevapharm.com

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO^® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO^® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY^® (BEPO^® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

Contact: communication@medincell.com

CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston

TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 22-25, 2026. The conferences will feature participants from across the global life sciences sector, including investors, scientists and representatives from leading pharmaceutical companies.

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as speaker in three conference programs and attend the invitation-only World Medical Innovation Forum. R&D Director Dr. Tali Kizhner will also represent the Company as a speaker at the 8^th Exosome-Based Therapeutics Development Summit.

The conferences are expected to provide opportunities for NurExone to present its development programs and engage with participants from across the biotechnology ecosystem, including investors, researchers, manufacturers and healthcare-industry participants.

Separately, Dr. Lior Shaltiel, Chief Executive Officer of NurExone, will be available for one-on-one investor meetings in New York, NY, from September 28 through September 30; investors interested in scheduling a meeting may contact nurexone@russopartnersllc.com.

“Boston brings together many of the people and organizations shaping the future of exosome therapeutics, including scientists, industry leaders and investors,” said Dr. Shaltiel. “Our recently announced U.S. manufacturing memorandum of understanding with Made Scientific reflects our objective of establishing a commercial platform in the United States. Our participation in these events will provide an opportunity to present our development programs and engage with industry participants.”

One Week, One City, Four Events

8th Exosome-Based Therapeutics Development Summit — September 22–24, 2026

Dr. Shaltiel and Dr. Kizhner are both confirmed speakers at the specialist conference dedicated to advancing exosome and extracellular-vesicle therapeutics. Dr. Shaltiel will participate as a panellist on Wednesday morning in the panel “Building investor confidence in the exosome space”. Additionally, on Thursday, Sep 24^th morning, Lior will lead the roundtable: “Understanding Investor Perspectives on Exosome Therapeutics to Navigate Risk Reward Clinical Validation & Platform Scalability in a Growing Field.”

Dr. Kizhner will also participate as a member of the conference’s expert speaker faculty, bringing NurExone’s scientific, development and manufacturing perspective to discussions around translating exosome therapeutics toward clinical and commercial development.

LSX Congress USA — September 22–24, 2026

Dr. Shaltiel will be part of the panel “Proof to Payoff: Building and Financing Translation-Ready Biotechs” on September 23 in a session that will address fundable development milestones, financing structures and organizational models for biotechnology companies moving promising science toward commercialization.

BioProcess International — September 22–25, 2026

On September 25, Dr. Shaltiel will present: “Unlocking the Regenerative Potential of Exosomes: From Bioprocess Development to Advanced Drug Delivery Platform.” The presentation will focus on the intersection of exosome bioprocess development, scalable manufacturing and the potential use of exosomes as advanced therapeutic delivery vehicles.

World Medical Innovation Forum — September 22–23, 2026

Dr. Shaltiel will also attend the invitation-only World Medical Innovation Forum, presented by Mass General Brigham and Bank of America. The Forum brings together senior healthcare executives, investors, clinicians, scientists and industry leaders to examine emerging technologies, manufacturing, investment, regulatory challenges and other issues shaping the future of healthcare.

NurExone’s participation across the four events comes as the Company continues to advance its lead therapeutic candidate, ExoPTEN, toward clinical development for acute spinal cord injury while pursuing initiatives intended to support future U.S. manufacturing and commercial activities.

Investor Awareness Engagement with RedChip

The Company has entered into a non-exclusive investor relations agreement dated September 8, 2026 with RedChip Companies, Inc. (“RedChip”), an arm’s-length service provider based in Maitland, Florida. RedChip will write, produce and distribute a 30-second television advertisement for the Company as part of a two-week national television campaign expected to include 40 airings on either Fox Business National TV or CNBC National TV. David Gentry, RedChip’s Chief Executive Officer, is the principal responsible for the engagement.

Subject to acceptance by TSX Venture Exchange (the “TSXV”), the agreement has an initial 90-day term commencing on the later of September 8, 2026 and the date of TSXV acceptance. The Company will pay RedChip a one-time cash fee of US$65,000. RedChip will not receive any securities of the Company as compensation. RedChip has represented to the Company that neither RedChip nor, to its knowledge after reasonable inquiry, its directors, officers, principals, control persons, key employees, contractors, subcontractors or other persons performing services under the agreement currently own or control any securities of the Company or have any right or present intention to acquire such securities. RedChip will not commence providing services until TSXV acceptance has been obtained.

About RedChip

RedChip Companies, Inc. is an investor relations, media and research firm focused on microcap and small-cap companies. Founded in 1992, RedChip provides investor relations and communications services, including investor outreach, retail and institutional roadshows, digital media, investor webinars, research distribution and strategic consulting. For more information, visit www.redchip.com.

About NurExone

NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws, together referred to as “forward-looking statements.” Forward-looking statements are based on expectations, estimates and assumptions as of the date of this news release and are generally identifiable by words such as “expects,” “intends,” “plans,” “anticipates,” “will,” “may,” “continues,” “toward,” “subject to” and similar expressions.

Forward-looking statements in this news release include statements concerning: the expected participation of the Company’s representatives in the conferences and sessions described in this news release; the anticipated timing and subject matter of those conferences and sessions; the opportunities that the conferences may provide for the Company to present its development programs and engage with industry participants and other stakeholders; the continued development of ExoPTEN; the Company’s evaluation of potential U.S. manufacturing activities under or in connection with its previously announced memorandum of understanding; acceptance of the RedChip agreement by TSXV; the expected commencement, timing, scope and delivery of the services to be provided by RedChip; the anticipated production, distribution and airing of the Company’s television advertisement; and the expected number and media channels of the television airings described in this news release.

The forward-looking statements are based on assumptions that management considers reasonable as of the date of this news release, including that the conferences, sessions and speaking engagements will proceed at the times and in the manner currently scheduled; that conference organizers, RedChip, media providers and other relevant third parties will fulfil their respective commitments; that the Company’s representatives will participate as planned; that TSXV will accept the RedChip agreement on terms acceptable to the Company; that appropriate television airtime will be available; that the Company and RedChip will agree upon and approve the final campaign scope, script, storyboard, disclaimers, distribution channels and timing; that RedChip will provide the services in accordance with the agreement; that the Company will have sufficient personnel and financial resources to undertake the activities described; and that required technical, regulatory, contractual and funding conditions relating to the Company’s development and manufacturing activities can be satisfied.

Forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from those expressed or implied, including changes to or cancellation of conferences, sessions, schedules or speaking engagements; the possibility that participation in the conferences will not result in any financing, commercial arrangement, collaboration or other business opportunity; the possibility that TSXV will not accept the RedChip agreement, or will require amendments or impose conditions; delays in campaign development or commencement; the unavailability or substitution of anticipated media channels or airtime; the possibility that the anticipated number of airings will not occur; the possibility that the RedChip campaign will not increase investor awareness or produce any commercial, financing or market benefit; reliance on RedChip, conference organizers, media providers and other third parties; the early-stage nature of the Company’s development programs; uncertainty associated with preclinical and clinical development and regulatory review; the Company’s ability to obtain sufficient financing; manufacturing-development, scale-up and technology-transfer risks; the possibility that activities contemplated by the Company’s manufacturing memorandum of understanding may not proceed on the terms or timeline currently anticipated, or at all; and the risks described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this news release. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 53,700 shares of the Company’s common stock (“Stock Options”) and an aggregate of 98,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Stock Options have a ten-year term and an exercise price per share of $31.93, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of September 15, 2027, September 15, 2028, September 15, 2029 and September 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.

About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748

EXTON, Pa., Sept. 18, 2026 (GLOBE NEWSWIRE) — Omega Flex, Inc. (the “Company”) today announced that the Board of Directors declared a regular quarterly dividend of $0.34 per share payable on October 14, 2026, to shareholders of record on September 30, 2026. In determining the amount of future regular quarterly dividends, the Board will review the cash needs of the Company, and based on results of operations, financial condition, capital expenditure plans, and consideration of possible acquisitions, as well as such other factors as the Board of Directors may consider relevant, determine on a quarterly basis the amount of a regular quarterly dividend.

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements, which are subject to inherent uncertainties which are difficult to predict and may be beyond the ability of Omega Flex to control. Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are not historical facts, but rather reflect Omega Flex’s current expectations concerning future results and events. The words “believes,” “expects,” “intends,” “plans,” “anticipates,” “hopes,” “likely,” “will,” and similar expressions identify such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance, or achievements of Omega Flex (or entities in which Omega Flex has interests) or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s view only as of the date of this press release. Omega Flex undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions, or circumstances.

Contact: Dean W. Rivest
(610) 524-7272

Underscores Enact’s Continued Strong Performance and Robust Capital Position

RALEIGH, N.C., Sept. 18, 2026 (GLOBE NEWSWIRE) — Enact Holdings, Inc. (Nasdaq: ACT) (Enact) a leading provider of private mortgage insurance through its insurance subsidiaries, today announced that AM Best upgraded the insurance financial strength rating for our flagship insurance subsidiary, Enact Mortgage Insurance Corporation, and our operating insurance subsidiary, Enact Mortgage Insurance Corporation of North Carolina, to A from A-. AM Best also announced the upgrade of Enact Holdings, Inc.’s long-term issuer rating, to bbb from bbb-. The outlook for the ratings is stable.

“This represents Enact’s first upgrade from AM Best since they initiated coverage in 2023 and reflects our ability to consistently execute and deliver strong performance,” said Rohit Gupta, Enact’s President and Chief Executive Officer. “We remain confident in our business and in our ability to serve our lenders and their borrowers while also generating value for our shareholders.”

Additional information regarding the rating changes can be found in the full report issued by AM Best.

About Enact Holdings, Inc.
Enact (Nasdaq: ACT), operating principally through its wholly-owned subsidiary Enact Mortgage Insurance Corporation since 1980, is a leading U.S. private mortgage insurance provider committed to helping more people achieve the dream of homeownership. Building on a deep understanding of lenders’ businesses and a legacy of financial strength, we partner with lenders to bring best-in class service, leading underwriting expertise, and extensive risk and capital management to the mortgage process, helping to put more people in homes and keep them there. By empowering customers and their borrowers, Enact seeks to positively impact the lives of those in the communities in which it serves in a sustainable way. Enact is headquartered in Raleigh, North Carolina.

CONTACT: Investor Contact
Jonathan Fleetwood
EnactIR@enactmi.com

Media Contact
Sarah Wentz
Sarah.Wentz@enactmi.com

Not for distribution in the United States or dissemination through U.S. news or wire services

TORONTO, Sept. 18, 2026 (GLOBE NEWSWIRE) — Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today that it has priced a private placement offering (the “Offering”) of $300 million aggregate principal amount of senior unsecured debentures (the “Debentures”) maturing March 29, 2030. The Debentures are being offered on a private placement basis in each of the provinces of Canada by a syndicate of agents led by BMO Capital Markets, Desjardins Capital Markets and RBC Capital Markets as joint bookrunners, and which includes National Bank Capital Markets, Scotia Capital, CIBC Capital Markets, ATB Cormark Capital Markets and TD Securities.

The Debentures will be issued at a price of $1,000 per $1,000 principal amount and bear interest at a fixed annual rate of 4.563% per annum, payable in equal semi-annual instalments in arrears on March 29 and September 29 in each year, commencing on March 29, 2027 until maturity, unless redeemed at an earlier date. The Debentures will be direct senior unsecured obligations of the REIT and will rank equally and rateably with all other unsecured and unsubordinated indebtedness of the REIT, except to the extent prescribed by law.

It is a condition of closing of the Offering that the Debentures be rated at least BBB (low) with a Stable trend by Morningstar DBRS. The REIT intends to use the net proceeds from the Offering to repay existing indebtedness and for general trust purposes. The closing of the Offering is expected to take place on or about September 29, 2026.

The Debentures have not been and will not be qualified for sale to the public under applicable securities laws in Canada and, accordingly, any offer or sale of the Debentures in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. The Debentures have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the United States and, accordingly, may not be offered, sold or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, U.S. Persons (as defined in the U.S. Securities Act) except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. The Debentures will not be listed on any stock exchange and there will be no market for such securities. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Debentures in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Nexus Industrial REIT

Nexus is a growth-oriented real estate investment trust focused on increasing unitholder value through the acquisition of industrial properties located in primary and secondary markets in Canada, and the ownership and management of its portfolio of properties. The REIT currently owns a portfolio of 87 properties comprising approximately 12.3 million square feet of gross leasable area. The REIT has approximately 97,097,000 voting units issued and outstanding, including approximately 74,276,000 REIT Units and approximately 22,821,000 Class B LP Units of subsidiary limited partnerships of Nexus, which are convertible to REIT Units on a one-to-one basis.

Forward-Looking Disclaimer

Certain statements contained in this news release constitute forward-looking statements which reflect the REIT’s current expectations and projections about future results, including statements regarding: the date of closing, the rating of the Debentures by Morningstar DBRS, and the use of proceeds from the Offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the REIT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Such forward-looking statements are based on a number of assumptions that may prove to be incorrect.

While the REIT anticipates that subsequent events and developments may cause its views to change, the REIT specifically disclaims any obligation to update these forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the REIT’s views as of any date subsequent to the date of this news release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Material risk factors and assumptions include those set out in the REIT’s most recent management’s discussion and analysis and annual information form, which are available on SEDAR+, and in the REIT’s other materials filed with the Canadian securities regulatory authorities from time to time. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates.

For further information please contact:

Kelly C. Hanczyk, CEO at (416) 906-2379; or        
Mike Rawle, CFO at (647) 823-1381.

IRVINE, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — Phoenix Energy One, LLC (“Phoenix Energy” or the “Company”), an energy company focused on oil and gas exploration and production across key U.S. basins, with a primary footprint in the Williston Basin in North Dakota and Montana, announced today its board of directors has authorized a cash distribution for the Series A Cumulative Redeemable Preferred Shares (the “Preferred Shares”) of $0.625 per Preferred Share to holders of record as of the close of business on October 1, 2026, which distribution will be paid on October 15, 2026.

The announced distribution is consistent with and made pursuant to the terms of the share designation for the Preferred Shares attached to the Third Amended and Restated Limited Liability Company Agreement of the Company, which is available on Edgar through the SEC’s website and is based on the stated liquidation preference of $25.00 per Preferred Share (calculated on a 360-day year of twelve 30-day months) at a rate of 10.00% per annum for the period from and including July 15, 2026 to and excluding October 15, 2026.

The Company’s Preferred Shares are listed on the NYSE American LLC (NYSE MKT: PHXE.P) and might appear stylized as PHXE-P, PHXE-PR, or PHXE/P on different brokerage platforms. The preferred shares have been listed since September 30, 2025.

To learn more about Phoenix Energy, visit the Company’s website at https://phoenixenergy.com.

About Phoenix Energy 

Founded in 2019 and headquartered in Irvine, California, Phoenix Energy is an innovative energy company specializing in oil production, mineral rights royalty acquisition, and non-operating working interests. Phoenix Energy’s drilling operations are currently focused on the Williston Basin (North Dakota and Montana), as well as the Powder River and Denver-Julesburg Basins (Wyoming and Colorado). Its royalty and working interest acquisitions target mineral, leasehold, overriding, and perpetual royalty interests across major U.S. basins.

Disclaimer

This press release contains forward-looking statements, which are statements regarding all matters that are not historical facts and include statements regarding Phoenix Energy’s current views, hopes, intentions, beliefs, or expectations concerning, among other things, its results of operations, financial condition, liquidity, prospects, growth, strategies, and position in the markets and the industries in which it operates. These forward-looking statements are generally identifiable by forward looking terminology such as “expect,” “believe,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “seek,” “estimate,” “should,” “will,” “approximately,” “predict,” “potential,” “may,” and “assume,” as well as variations of such words and similar expressions referring to the future.

Contact

Company: Phoenix Energy One, LLC
Email: InvestorRelations@phoenixenergy.com 
Address: 18575 Jamboree Road, Suite 830, Irvine, CA 92612
Phone: 949-416-5037

HAMBURG, Germany and AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), a global provider in high-power EV charging solutions, today reported its unaudited financial results for the six months ended June 30, 2026.

Mr. Yifei (“Simon”) Hou, Co-Chief Executive Officer of XCharge, commented, “While customer procurement timing and changes in project schedules affected the pace of revenue and deliveries in the first half of 2026, we remained focused on executing our long-term growth strategy. We made important commercial and product progress during the period. Our long-term partnership with EnBW marked a significant commercial milestone in Europe, while the introduction of the new-generation C7 and the launch of GridOne expanded our ability to address customers’ evolving charging and energy management needs. Looking ahead, we expect business activity to accelerate meaningfully in the second half of the year as we fulfill scheduled customer deliveries and advance existing customer programs and projects. We believe the commercial progress we have made, together with our expanded product portfolio, positions us well to capture the opportunities ahead.”

Mr. Joel A. Gallo, Chief Financial Officer, added, “The financing completed in June provided additional liquidity to support our operations. As we prepare for higher anticipated activity in the second half, we will continue to maintain disciplined cost and working capital management, improve operational efficiency, and allocate resources to customer programs and areas with the clearest commercial potential. Our priority is to support renewed revenue growth while continuing to improve the underlying financial performance of the business.”

		For the Six Months Ended
		June 30,
		2026				2025
		(dollars in thousands)
Revenues	$		10,271		$		12,451
Gross margin			38.8	%			51.3	%
Operating loss	$		(11,184	)	$		(7,436	)
Net loss	$		(11,126	)	$		(7,338	)
Loss per Class A and Class B ordinary share–Basic and diluted	$		(0.004	)	$		(0.003	)

Outlook

The Company expects business performance to improve significantly in the second half of 2026, driven primarily by scheduled deliveries under existing customer orders. The Company expects full-year 2026 revenue to be in the range of $32.9 million to $38.2 million, representing year-over-year growth of approximately 31% to 52%. This outlook reflects management’s current expectations regarding customer orders, production and delivery schedules, market conditions and other factors as of the date of this press release, and is subject to change.

Operating Highlights and Recent Announcements

• Deliveries: Total EV charger deliveries were 262 units in the first half of 2026, representing a decrease of 44.5% year over year. This included 253 DC fast chargers, representing a decrease of 44.3%, and 9 NZS and GridLink chargers, representing a decrease of 50%.
• Entered the Energy Storage Market with the Launch of GridOne. In June, XCharge launched GridOne, an all-in-one photovoltaic and energy storage system for commercial and industrial applications, at ees Europe, a leading European exhibition for batteries and energy storage systems. GridOne combines 125 kW of power conversion capacity, a 215 kWh lithium iron phosphate battery and optional 50 kW photovoltaic maximum power point tracking in an integrated system designed for applications including peak shaving, solar self-consumption, EV charging load buffering and backup power.
• Unveiled the New Generation of the C7 DC Fast-Charging Station. In June, XCharge presented the new generation of its C7 DC fast-charging station at Power2Drive Europe. Offering charging power of up to 480 kW, the upgraded C7 is designed to provide greater reliability, scalability and serviceability across public charging, commercial fleet, retail and other high-traffic applications.
• Appointed Albina Iljasov as Co-Chief Executive Officer. Effective as of June 1, 2026, XCharge appointed Albina Iljasov as Co-Chief Executive Officer to serve alongside Simon Hou. Ms. Iljasov primarily oversees the Company’s European operations and related strategic initiatives and has primary responsibility for its information security and cybersecurity initiatives.
• Entered into a Long-Term Partnership with EnBW. In March, XCharge entered into a multi-year framework agreement with EnBW, Germany’s largest fast-charging network operator, covering the supply and joint development of fast-charging hardware and software. The partnership followed a field test involving ten XCharge C7 ultra-fast chargers across four EnBW locations, which completed more than 20,000 charging sessions.
• Entered into a Registered Direct Offering. In June, XCharge entered into a securities purchase agreement with a global institutional investor for the sale of 7.0 million ADSs in a registered direct offering, generating gross proceeds of approximately $4.4 million before deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds for working capital and general corporate purposes.
• Implemented an ADS Ratio Change. Effective as of August 21, 2026, XCharge changed the ratio of its ADSs to its Class A ordinary shares from one ADS representing 40 Class A ordinary shares to one ADS representing 800 Class A ordinary shares. The ADS ratio change had the same effect as a one-for-20 reverse ADS split for ADS holders. The Company’s Class A ordinary shares were not affected, and its ADSs continue to trade on the Nasdaq Global Market under the symbol “XCH.”
• Change in Management Position. Effective as of September 7, 2026, Aatish V Patel transitioned from President of the Company to General Manager of XCharge Energy USA Inc., the Company’s wholly-owned U.S. subsidiary, to support the continued expansion of its U.S. operations.
• Regained Compliance with Nasdaq Minimum Bid Price Requirement. On September 8, 2026, the Company received confirmation from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement and that the matter is now closed.

Financial Summary for the First Half of 2026

Unless otherwise noted, the following figures refer to the first half of 2026 and comparisons are with the first half of 2025.

• Revenues were $10.3 million, representing a decrease of 17.5% from $12.5 million. Product revenues were $9.5 million, compared with $12.1 million, while service revenues increased to $0.8 million from $0.4 million. The decrease in revenue was primarily attributable to the timing of customer procurement decisions and project deliveries, including temporary delays beginning in late 2025 amid trade policy uncertainty and evolving renewable energy regulations. Despite the lower level of recognized revenue in the first half, order volume increased compared with the prior-year period, supporting the Company’s expectation for significantly higher revenue in the second half of 2026.
• Cost of revenues was $6.3 million, up 3.6% from $6.1 million, primarily reflecting higher input costs for certain components and raw materials and foreign currency exchange effects.
• Gross margin was 38.8%, compared with 51.3%. The decrease was primarily due to the increased proportion of lower-margin products in the sales mix. In addition, the rise in prices of precious metals such as silver and copper also increased the purchase cost of spare parts and led to an increase in cost of sales and a decrease in gross profit. The Company continues to pursue pricing, sourcing and operating initiatives intended to mitigate these cost pressures.
• Operating expenses were $15.2 million, up 9.2% from $13.9 million.
  • Selling and marketing expenses were $5.8 million, representing an increase of 12.7% from $5.2 million. The increase was primarily due to higher marketing expenses associated with the introduction of the Company’s new GridOne product, which was unveiled earlier this year.
  • Research and development expenses were $2.3 million, representing a decrease of 42.7% from $4.1 million. The decrease primarily reflected the non-recurrence of certain development expenditures incurred in the first half of 2025, including third-party system-development costs associated with new product initiatives. The Company continued to invest in the development and enhancement of its charging and energy solutions during the first half of 2026.
  • General and administrative expenses were $7.0 million, representing an increase of 51.3% from $4.6 million. The increase primarily reflected higher professional service expenses, including legal, audit and compliance costs, as well as other costs associated with operating as a U.S.-listed public company, and the shift from foreign currency exchange gain to loss. The increase was partially offset by lower share-based compensation.
• Operating loss was $11.2 million, compared with an operating loss of $7.4 million, primarily reflecting lower gross profit resulting from lower revenue and gross margin, together with higher general and administrative and selling and marketing expenses, partially offset by lower research and development expenses.
• Net loss was $11.1 million, compared with a net loss of $7.3 million. Non-GAAP net loss, which excludes the effect of share-based compensation and changes in fair value of financial instruments, was $10.4 million, compared with a non-GAAP net loss of $4.6 million.
• Basic and diluted loss per Class A and Class B ordinary share was $0.004, compared with a loss per share of $0.003. Non-GAAP basic and diluted loss per Class A and Class B ordinary share, which excludes the effect of share-based compensation and changes in fair value of financial instruments, was $0.003, compared with a non-GAAP loss per share of $0.002.
• Cash and cash equivalents plus restricted cash were $11.4 million as of June 30, 2026, compared with $13.9 million as of December 31, 2025. The decrease primarily reflected cash used in operating activities, partially offset by financing activities, including proceeds from the registered direct offering completed in June 2026. The Company continues to actively manage liquidity and working capital while supporting anticipated higher business activity in the second half of the year.

Use of Non-GAAP Financial Measures

We consider non-GAAP net loss and non-GAAP basic and diluted loss per Class A and Class B ordinary share as supplemental measures to review and assess our operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We also believe that the use of these non-GAAP measures facilitates investors’ assessment of our operating performance.

These non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. These non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using these non-GAAP financial measures is that they do not reflect all items of income and expense that affect our operations. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. We compensate for these limitations by reconciling these non-GAAP financial measures to the nearest U.S. GAAP performance measures, all of which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

We define non-GAAP net loss as net loss excluding share-based compensation and changes in fair value of financial instruments. We define non-GAAP basic and diluted loss per Class A and Class B ordinary share as non-GAAP net loss divided by the weighted average number of Class A and Class B ordinary shares outstanding during the period. For more information on these non-GAAP financial measures, please see the tables captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this release.

Exchange Rate Information

This release contains translations of certain Euro and Renminbi amounts into U.S. dollars solely for the convenience of the reader. Unless otherwise noted, translations were made at EUR0.8759 to $1.00 and RMB6.7851 to $1.00, based on the exchange rates as of June 30, 2026 published in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that any amounts could have been, or could be, converted into another currency, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “objective,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the United States Securities and Exchange Commission.

All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

About XCharge

XCharge (Nasdaq: XCH) is a global provider in high-power electric vehicle charging solutions. The Company has headquarters in Hamburg, Germany and Austin, TX, working with a globally networked team to drive innovation in the field of energy and help its customers achieve long-term success.

For investor and media inquiries, please contact:
XCHG Limited
IR Department
Email: ir@xcharge.com 

Water Tower Research Asia
Feifei Shen, CFA
Tel: +86 134-6656-6136
Email: feifei@watertowerresearch.com 

XCHG LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
		As of December 31,				As of June 30,
		2025				2026
		US$				US$
ASSETS
Current assets
Cash and cash equivalents			11,385,381				8,855,514
Restricted cash			2,522,898				2,557,464
Accounts receivable, net			7,005,396				6,452,834
Amounts due from related parties			2,517,833				1,734,333
Inventories, net			9,432,929				13,832,492
Prepayments and other current assets			4,246,959				3,023,022
Total current assets			37,111,396				36,455,659
Non–current assets
Property and equipment, net			1,972,396				2,008,436
Long-term investments			106,704				110,536
Operating lease right-of-use assets, net			1,766,194				1,524,016
Other non-current assets			1,711,830				1,101,478
Total non–current assets			5,557,124				4,744,466
Total assets			42,668,520				41,200,125
LIABILITIES
Current liabilities
Short-term borrowings			6,402,231				8,105,997
Accounts payable			6,727,086				8,320,524
Contract liabilities			4,074,505				6,510,896
Operating lease liabilities—current			592,989				468,274
Financial liability			63,593				24,192
Amounts due to a related party			164,046				159,996
Accrued expenses and other current liabilities			5,513,404				6,068,318
Total current liabilities			23,537,854				29,658,197
Non–current liabilities
Operating lease liabilities—non-current			1,175,413				1,075,871
Other non-current liabilities			88,898				28,089
Total non–current liabilities			1,264,311				1,103,960
Total liabilities			24,802,165				30,762,157
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Class A ordinary shares (USD0.00001 par value; 4,258,745,553 shares authorized; 2,160,310,915 and 2,799,892,915 shares issued, and 2,160,310,915 and 2,459,892,915 shares outstanding, as of December 31, 2025 and June 30, 2026, respectively; the shares issued as of June 30, 2026 include 340,000,000 escrowed reserve shares under the ATM Program.)			21,603				27,999
Class B ordinary shares (USD0.00001 par value; 741,254,447 shares authorized, issued and outstanding as of December 31, 2025 and June 30, 2026)			7,413				7,413
Additional paid – in capital			100,820,027				105,035,759
Accumulated other comprehensive income			1,893,379				1,369,044
Accumulated deficit			(84,876,067	)			(96,002,247	)
Total shareholders’ equity			17,866,355				10,437,968
Total liabilities and shareholders’ equity			42,668,520				41,200,125

XCHG LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
		For the Six Months Ended June 30,
		2025				2026
		US$				US$
Revenues (including sales to a related party of US$753,827 and US$226 for the six months ended June 30, 2025 and 2026, respectively)			12,451,126				10,270,989
Cost of revenues (including purchase from a related party of US$147,611 and US$526 for the six months ended June 30, 2025 and 2026, respectively)			(6,069,788	)			(6,290,301	)
Gross profit			6,381,338				3,980,688
Operating expenses:
Selling and marketing expenses			(5,186,741	)			(5,843,734	)
Research and development expenses			(4,084,917	)			(2,339,474	)
General and administrative expenses			(4,619,965	)			(6,989,407	)
Total operating expenses			(13,891,623	)			(15,172,615	)
Government grants			73,825				8,181
Operating loss			(7,436,460	)			(11,183,746	)
Changes in fair value of financial instruments			106,289				41,217
Interest expenses			(75,149	)			(64,515	)
Interest income			67,190				80,864
Loss before income taxes			(7,338,130	)			(11,126,180	)
Income tax expense			—			—
Net loss			(7,338,130	)			(11,126,180	)
Other comprehensive income (loss)
Foreign currency translation adjustment, net of nil income taxes			(52,090	)			(524,335	)
Comprehensive loss			(7,390,220	)			(11,650,515	)
Loss per Class A and Class B ordinary share–Basic and diluted			(0.003	)			(0.004	)
Weighted average number of Class A and Class B ordinary shares – Basic and diluted			2,544,609,189				3,128,519,848

XCHG LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
		For the Six Months Ended June 30,
		2025				2026
		US$				US$
Cash flows from operating activities:
Net cash used in operating activities			(6,815,957	)			(7,470,588	)
Cash flows from investing activities:
Cash paid for purchase of property and equipment and intangible assets			(311,025	)			(273,477	)
Loans provided to a third party			—				(29,144	)
Net cash used in investing activities			(311,025	)			(302,621	)
Cash flows from financing activities:
Proceeds from short-term bank borrowings			1,391,999				4,371,674
Repayment of short-term bank borrowings			(3,945,105	)			(2,914,449	)
Proceeds from sale of ordinary shares through follow-up offering, net of placement agent fees and other reimbursable expenses $480,312			—				3,894,688
Payments of follow-up offering cost			(956,248	)			(230,389	)
Net cash (used in) provided by financing activities			(3,509,354	)			5,121,524
Effect of foreign currency exchange rate changes on cash and cash equivalents and restricted cash			199,983				156,384
Net increase (decrease) in cash, cash equivalents and restricted cash			(10,436,353	)			(2,495,301	)
Cash, cash equivalents and restricted cash at the beginning of the period			26,773,902				13,908,279
Cash, cash equivalents and restricted cash at the end of the period			16,337,549				11,412,978
Supplemental cash flow information:
Interest paid			73,886				63,655
Non-cash investing and financing activities:
Accrual of ATM program cost			—				5,385
Offering costs charged against additional paid-in capital			—				894,379
Operating right-of-use assets obtained in exchange for operating lease liabilities			874,106			—
Property and equipment transferred from inventories			874,663			—
ROU assets disposed as reduction of operating lease liabilities due to lease termination			—				26,029
Reconciliation of the amount for cash, cash equivalents and restricted cash:
Cash and cash equivalents			16,337,549				8,855,514
Restricted cash			—				2,557,464
Total cash, cash equivalents and restricted cash			16,337,549				11,412,978

XCHG LIMITED UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS
		For the Six Months Ended
		June 30,
		2025				2026
		US$				US$
Net loss			(7,338,130	)			(11,126,180	)
Add: share-based compensation			2,843,701				741,506
Less: changes in fair value of financial instruments			106,289				41,217
Non-GAAP net loss			(4,600,718	)			(10,425,891	)
Loss per Class A and Class B ordinary share–Basic and diluted			(0.003	)			(0.004	)
Add: share-based compensation			0.001				0.001
Less: changes in fair value of financial instruments		—				—
Non-GAAP Loss per Class A and Class B ordinary share – Basic and diluted			(0.002	)			(0.003	)

WUXI, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — LOBO TECHNOLOGIES LTD. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative electric mobility vehicles manufacturer and seller, today announced its unaudited financial results for the first half of fiscal year 2026 ended June 30, 2026.

Mr. Huajian Xu, Chief Executive Officer of LOBO, commented, “We delivered encouraging progress in the first half of 2026, with total revenues increasing 20.6% year over year. Our core electric vehicles and accessories business remained resilient, generating 8.2% revenue growth, while our newly launched AI infrastructure services business contributed approximately $1.5 million in revenue and began to broaden our revenue base.

“At the same time, we continued to sharpen our cost structure and improve operating efficiency, with total operating expenses decreasing 17.9% year over year and our net loss narrowing meaningfully compared with the prior-year period. These results reflect our focus on balancing growth investment with greater financial discipline.

“Looking ahead, we will continue to strengthen our core electric mobility business while selectively pursuing technology-driven opportunities that complement our capabilities and expand our growth potential. We remain focused on disciplined execution, efficient capital allocation and building sustainable long-term value for our shareholders.”

First Half of Fiscal Year 2026 Financial Summary

• Revenues were $14.6 million for the first half of fiscal year 2026, an increase of 20.6% from $12.1 million for the same period of last year.
• Gross profit was $1.9 million for the first half of fiscal year 2026, relatively stable compared to $1.9 million for the same period of last year.
• Gross profit margin was 13.2% for the first half of fiscal year 2026, compared to 16.1% for the same period of last year.
• Net loss was $1.1 million for the first half of fiscal year 2026, compared to $2.6 million for the same period of last year.
• Basic and diluted loss per share were $0.07 for the first half of fiscal year 2026, compared to $0.28 for the same period of last year.

First Half of Fiscal Year 2026 Financial Results

Revenues

Revenues were $14.6 million for the first half of fiscal year 2026, an increase of 20.6% from $12.1 million for the same period of last year. Revenues from electric vehicles and accessories sales increased by 8.2%, to $13.1 million for the first half of fiscal year 2026, from $12.1 million for the same period of last year, and the Company generated $1.5 million of revenues from its new AI infrastructure services business.

• Revenue from two-wheeled e-bicycles was $8.1 million for the first half of fiscal year 2026, an increase of 21.71% from $6.7 million for the same period of last year.
• Revenue from two-wheeled e-mopeds was nil for the first half of fiscal year 2026, compared to $36,778 for the same period of last year.
• Revenue from three-wheeled electric vehicles was $2.2 million for the first half of fiscal year 2026, a decrease of 29.22% from $3.1 million for the same period of last year.
• Revenue from four-wheeled electric off-highway shuttles was $0.9 million for the first half of fiscal year 2026, an increase of 143.51% from $0.4 million for the same period of last year.
• Revenue from batteries was $0.9 million for the first half of fiscal year 2026, a decrease of 46.75% from $1.7 million for the same period of last year.
• Revenue from parts and accessories was $1.0 million for the first half of fiscal year 2026, an increase of 345.36% from $0.2 million for the same period of last year.

Cost of Revenues

Cost of revenue was $12.7 million for the first half of fiscal year 2026, an increase of 24.8% from $10.1 million for the same period of last year. The increase primarily due to the growth in electric vehicles and accessories sales and the addition of $1.3 million of cost of revenues associated with the Company’s new AI infrastructure services business.

Gross Profit

Gross profit was $1.9 million for the first half of fiscal year 2026, relatively stable compared to $1.9 million for the same period of last year. Gross profit margin was 13.2% for the first half of fiscal year 2026, compared to 16.1% for the same period of last year.

Operating Expenses

Total operating expenses were $2.5 million for the first half of fiscal year 2026, a decrease of 17.9% from $3.1 million for the same period of last year.

• Selling and marketing expenses were $0.4 million for the first half of fiscal year 2026, an increase from $0.3 million for the same period of last year, primarily due to higher salary expenses and freight costs associated with higher sales volume.
• General and administrative expenses were $0.8 million for the first half of fiscal year 2026, decreased from $1.7 million for the same period of last year. The general and administrative expenses decrease primarily due to lower professional service fees incurred in the six months ended June 30, 2026.
• Research and development expenses were $1.3 million for the first half of fiscal year 2026, an increase from $1.1 million for the same period of last year, primarily due to the Company’s continued investment in developing its platform related AI infrastructure.

Net Loss

Net loss was $1.1 million for the first half of fiscal year 2026, compared to $2.6 million for the same period of last year.

Basic and Diluted Loss per Share

Basic and diluted loss per share were $0.07 for the first half of fiscal year 2026, compared to $0.28 for the same period of last year.

Financial Condition

As of June 30, 2026, the Company had cash and cash equivalents of $1.0 million, compared to $0.9 million as of December 31, 2025.

Net cash used in operating activities was $3.7 million for the first half of fiscal year 2026, compared to $1.2 million for the same period of last year.

Net cash used in investing activities was $0.6 million for the first half of fiscal year 2026, compared to net cash provided by investing activities of $0.1 million for the same period of last year.

Net cash provided by financing activities was $4.3 million for the first half of fiscal year 2026, compared to $0.6 million for the same period of last year.

About LOBO TECHNOLOGIES LTD.

LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO) is a manufacturer of electric mobility products. Its product portfolio includes electric bicycles, electric motorcycles, electric tricycles, electric off-road vehicles (such as golf carts and mobility scooters) as well as solar-powered vehicles.

LOBO is committed to promoting sustainable transportation through advanced technologies, with the goal of reducing carbon emissions and improving energy efficiency.

For more information about the Company, please visit: www.loboebike.com.

For more information about the Company’s Claw AI Agent platform and LoboToken.ai platform, please visit:

Claw AI Agent platform: www.loboaiclaw.com;

LoboToken.ai: www.lobotoken.ai.

Forward-Looking Statements

This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2026, and other filings with the SEC.

For more information, please contact:

LOBO TECHNOLOGIES LTD.
Zane Xu
Investor Relations Manager
Email: ir@loboai.com

Ascent Investor Relations LLC
Tina Xiao
Tel: +1-646-932-7242
Email: investors@ascent-ir.com

LOBO TECHNOLOGIES LTD
UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
(In U.S. dollars except for number of shares)
		As of
		June 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	980,746			$	908,341
Accounts receivable, net			3,922,979				3,107,520
Inventories, net			10,221,788				9,698,754
Short-term investments			49,962				747,709
Prepaid expenses and other current assets			3,281,862				3,366,882
Total current assets			18,457,337				17,829,206
Property and equipment, net			1,106,184				1,097,411
Intangible assets, net			121,037				308,553
Operating lease right-of-use assets, net			796,351				1,014,161
Long-term loan receivable			850,000				–
Deferred tax assets			182,882				247,309
Total Assets			21,513,791				20,496,640
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable		$	1,455,864			$	1,768,339
Contract liability			3,239,888				2,067,018
Other current payables			718,523				3,360,773
Taxes payable			1,739,791				1,414,938
Amounts due to related parties			163,625				38,564
Short-term loans			4,540,378				2,968,491
Operating lease liabilities, current			1,451,725				1,233,892
Total current liabilities			13,309,794				12,852,015
Long-term loan			14,990				95,441
Deferred tax liabilities			7,964				151,308
Operating lease liabilities, non-current			200,306				410,572
Total liabilities			13,533,054				13,509,336
Commitments and contingencies			–				–
Equity:
Class A Ordinary shares (US$0.001 par value per share; 90,000,000 and 90,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 10,711,618 and 8,838,194 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively)			10,712				8,839
Class B Ordinary shares (US$0.001 par value per share; 10,000,000 and 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 3,730,320 and 3,730,320 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively)			3,730				3,730
Additional paid-in capital			12,624,147				10,804,674
Accumulated deficit			(4,873,449	)			(3,795,004	)
Accumulated other comprehensive income/(loss)			51,153				(199,379	)
Statutory reserve			164,444				164,444
Total shareholders’ equity			7,980,737				6,987,304
Total Liabilities and Equity		$	21,513,791			$	20,496,640

LOBO TECHNOLOGIES LTD
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(In U.S. dollars except for number of shares)
		Six Months Ended June 30,
		2026				2025
Revenues		$	14,586,984			$	12,091,762
Cost of revenues			12,661,580				10,149,305
Gross Profit			1,925,404				1,942,457
Operating expenses
Selling and marketing expenses			423,358				338,080
General and administrative expenses			796,048				1,701,458
Research and development expenses			1,320,313				1,053,921
Total operating expenses			2,539,719				3,093,459
Operating loss			(614,315	)			(1,151,002	)
Other (expenses)/income
Interest expense			(60,464	)			(1,437,601	)
Gain on disposal of subsidiaries			–				50,545
Other (expenses)/income			(478,784	)			86,714
Total other (expenses)/income, net			(539,248	)			(1,300,342	)
Loss before income tax expense			(1,153,563	)			(2,451,344	)
Income tax (benefit)/expense			(75,118	)			170,825
Net Loss			(1,078,445	)			(2,622,169	)
Net Loss			(1,078,445	)			(2,622,169	)
Foreign currency translation adjustments			250,532				176,222
Total comprehensive loss			(827,913	)			(2,445,947	)
Net loss per share, basic and diluted		$	(0.07	)		$	(0.28	)
Weighted average shares outstanding, basic and diluted			14,678,842				9,368,223

LOBO TECHNOLOGIES LTD
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In USD)
		For the six months ended June 30,
		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(1,078,445	)		(2,622,169	)
Adjustment to reconcile net loss to net cash used in operating activities
Depreciation and amortization		284,556			364,331
Common stock issued for services		–			354,950
Investment loss/(income)		389,239			(20,113	)
Gain on disposal of subsidiaries		–			(50,545	)
Amortization of Convertible Note issuance cost and debt discount upon conversion		–			1,421,069
Amortization of operating lease right-of-use assets		246,095			–
Changes in Operating Assets and Liabilities
Accounts receivable, net		(1,702,930	)		(952,628	)
Inventories, net		(223,173	)		(1,726,797	)
Prepaid expenses and other current assets		172,286			3,358,866
Deferred tax asset		71,197			–
Deferred tax liabilities		(146,315	)		–
Accounts payable		(359,867	)		(648,149	)
Advance from customers		1,097,007			(1,212,522	)
Other current payables		(2,698,280	)		(14,258	)
Taxes payable		278,306			364,118
Operating lease Liabilities		(42,362	)		170,091
Net cash used in operating activities		(3,712,686	)		(1,213,756	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term investment		(810,815	)		(551,526	)
Sales of short-term investment		1,134,125			571,639
Proceeds from disposal of subsidiaries		–			206,822
Purchase of property and equipment		(51,475	)		(95,215	)
Payments for loans advanced to third parties		(850,000	)		–
Net cash (used in)/provided by investing activities		(578,165	)		131,720
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Class A ordinary shares and warrants		1,820,746			–
Proceeds from exercise of Pre-Funded Warrants		600
Proceeds of interest-free loan from related parties		1,677,783			382,484
Repayments of interest-free loan to related parties		(576,221	)		(1,180,782	)
Proceeds from short-term loan		2,185,824			1,481,385
Repayments of short-term loans		(728,608	)		–
Repayments of long-term loans		(75,448	)		(71,389	)
Net cash provided by financing activities		4,304,676			611,698
					–
Effect of exchange rate changes on cash and cash equivalents		58,580			4,959
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS		72,405			(465,379	)
CASH AND CASH EQUIVALENTS, beginning of period		908,341			1,889,590
CASH AND CASH EQUIVALENTS, end of period		980,746			1,424,211
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the period for:
Income taxes		4,200			–
Interest		72,686			(26,741	)
NON-CASH TRANSACTIONS
Common stock issued upon conversion of debt and accrued interest					1,382,664
Offsetting of the consideration receivable from disposal of subsidiary against other current payables					3,515,981
Offsetting of account receivables against amounts due to related parties		976,335			–